Cormedix INC

CorMedix Therapeutics announced robust second quarter 2026 financial results, including $101.9 million in consolidated revenue and $26.0 million in net income, while raising its full-year adjusted EBITDA guidance.

CorMedix Inc. announces preliminary approval of a settlement for consolidated shareholder derivative lawsuits, resolving claims through corporate governance reforms.

CorMedix Inc. announced a change in its independent registered public accounting firm, dismissing CBIZ CPAs P.C. and appointing Ernst & Young LLP.

CorMedix announced a significant legal victory as the U.S. Court of Appeals for the Federal Circuit affirmed a lower court's decision, ruling that Nexus Pharmaceuticals' generic minocycline product infringes CorMedix's patents.

CorMedix Therapeutics announced robust first quarter 2026 financial results, exceeding expectations with significant revenue and net income growth, and consequently raising its full-year financial guidance.

CorMedix Therapeutics reports positive topline results from its Phase III ReSPECT trial for REZZAYO (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients, meeting its primary endpoint.

CorMedix Inc. announced a substantial increase in revenue and net income for the second quarter of 2026, primarily fueled by the integration of Melinta Therapeutics and robust sales of DefenCath.

CorMedix Inc. reported a significant increase in revenue and net income for Q1 2026, driven by the integration of Melinta Therapeutics and strong performance of DefenCath.

CorMedix Inc. reports a significant revenue increase in Q3 2025, driven by strong DefenCath sales and the strategic acquisition of Melinta Therapeutics, despite ongoing legal challenges and increased operating expenses.

CorMedix Inc. reported a dramatic surge in Q2 2025 revenue and net income, driven by DefenCath sales, and announced the strategic acquisition of Melinta Therapeutics for $300 million.

CorMedix Inc. reports a profitable first quarter in 2025, driven by the commercialization of DefenCath, with revenue reaching $39.1 million.

CorMedix Inc. reported its first commercial revenue in the third quarter of 2024, driven by the launch of its antimicrobial catheter lock solution, DefenCath.

CorMedix Inc. reported significant revenue growth and net income in 2025, driven by the successful commercialization of DefenCath and the strategic acquisition of Melinta Therapeutics, despite facing future reimbursement challenges.

CorMedix Inc. achieves profitability in the fourth quarter of 2024, driven by DefenCath sales, as detailed in its annual 10-K filing.

CorMedix Inc. details the separation agreement with its former General Counsel and provides an overview of its financial performance and business activities in its annual report.

CorMedix Inc.'s Chief Legal Officer, Beth Zelnick Kaufman, acquired 36,006 shares of common stock through the vesting of performance stock units.

CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, achieved performance conditions for 36,006 stock units, subject to future time-based vesting.

CorMedix Inc. CEO Joseph Todisco has achieved performance conditions for 77,156 performance stock units, subject to future time-based vesting.

CorMedix Inc.'s EVP and CFO, Susan Blum, reported the acquisition of restricted stock units and the disposition of shares for tax withholding purposes.

CorMedix Chief Legal Officer Beth Zelnick Kaufman reported the grant of 72,820 restricted stock units and the disposition of 8,803 shares for tax withholding.

CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, was granted 93,010 restricted stock units, with a portion immediately vesting and the remainder vesting over three years.

CorMedix Inc. is holding its 2026 Annual Meeting of Stockholders on June 23, 2026, to vote on several proposals, including director elections, executive compensation, auditor ratification, and significant amendments to its corporate charter and preferred stock designations.

CorMedix Inc. calls a Special Meeting on November 10, 2025, to vote on critical proposals including removing an exchange cap for convertible notes and an acquisition, increasing its stock incentive plan, and ratifying past preferred stock amendments.

Cormedix Inc. announces its 2025 Annual Meeting of Stockholders to be held on June 24, 2025, outlining key voting items including the election of directors, executive compensation, and the ratification of the company's accounting firm.

CorMedix Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 24, 2025, to elect directors, approve executive compensation, and ratify the appointment of its independent accounting firm.

CorMedix Inc. will conduct its 2024 Annual Meeting of Stockholders virtually on November 21, 2024, to vote on key proposals including the election of directors and an amendment to the stock incentive plan.

CorMedix Inc. has acquired a significant stake in Talphera, Inc. and secured exclusive negotiation rights for a potential full acquisition, contingent on clinical trial results.

Individual investor Aymen Shaibatalhamd has filed an amendment reporting a 5.9% beneficial ownership stake in CorMedix Inc.

Individual investor Aymen Shaibatalhamd has filed an amended Schedule 13G reporting a 5.9% beneficial ownership stake in CorMedix Inc.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have collectively reported beneficial ownership of 7.94% of CorMedix Inc.'s common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in CorMedix Inc. following an internal realignment that disaggregated reporting.

Aymen Abdalkader Shaibatalhamd has disclosed a 5.83% beneficial ownership stake in CorMedix Inc., holding 4,600,000 shares.

Deep Track Capital, LP and affiliates have reported a beneficial ownership of 6.29% in CorMedix Inc., totaling 4,955,487 common shares.